Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease
Clinical Infectious Diseases · 2025
DOI: 10.1093/cid/ciaf079 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Infectious Diseases, 2025. Verfasst von Tessa Adzemovic und 11 weiteren Autor:innen. Beteiligte Einrichtung: Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda. Hauptthemen laut MEDLINE: HIV Infections, Tuberculosis, Lipopolysaccharides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 9 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, FIC NIH HHS, NIAID.
Abstract (Originalsprache)
Background
An urgent need exists for point-of-care diagnostics to detect tuberculosis (TB) among people with advanced human immunodeficiency virus (HIV) disease. The Fujifilm SILVAMP TB LAM (FujiLAM II) is a novel point-of-care assay that detects mycobacterial lipoarabinomannan (LAM) antigen in the urine to identify TB. We present a validation of the FujiLAM II assay on prospectively collected urine samples from outpatient adults with advanced HIV disease in Uganda.
Methods
We performed a prospective diagnostic accuracy study of the FujiLAM II assay among outpatients with advanced HIV disease at 16 clinics Uganda. FujiLAM II was run on cryopreserved urine. We determined diagnostic performance for the FujiLAM II test against the cases of confirmed TB (Xpert or mycobacterial culture positive) versus cases without TB. We additionally assessed sensitivity and specificity of the FujiLAM II assay as compared with confirmed TB among pre-specified subgroups: CD4 <100 cells/µL versus 100–200 cells/µL, antiretroviral therapy (ART) naive versus experienced, and CRP <5 mg/L versus ≥5 mg/L.
Results
Among 583 participants who had FujiLAM II testing performed, the FujiLAM II assay demonstrated 54% (25/46) (95% confidence interval [CI]: 40%–69%) sensitivity to identify confirmed TB and 95% (326/342) (95% CI: 93% to 98%) specificity to identify the absence of TB. Among participants with CD4 cell counts <100 cells/µL, FujiLAM II sensitivity was 69% (95% CI: 53%–85%) and specificity was 94% (95% CI: 90%–97%). Among participants with serum C-reactive protein (CRP) ≥5 mg/L, the FujiLAM II assay exhibited a sensitivity of 62% (95% CI: 46%–77%) and specificity of 93% (95% CI: 89%–98%).
Conclusions
FujiLAM II is a point-of-care, non-sputum based TB diagnostic with moderate sensitivity and high specificity in outpatients with advanced HIV disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious Diseases Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
- Department of Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- Department of Medicine, School of Medicine, College of Health Sciences, Makerere University, Kampala, Uganda.
ORCID-Profile: Elizabeth Nalintya, Spencer Yueh, Biyue Dai, David B Meya, David R Boulware, Radha Rajasingham
Förderung
- NIAID NIH HHS
- FIC NIH HHS
- NIAID
Zitieren
APA
Adzemovic, T., Nalintya, E., Fieberg, A., Mande, E., George, K., Yueh, S., Namakula, O., Nerima, P., Dai, B., Meya, D. B., Boulware, D. R., & Rajasingham, R. (2025). Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease. Clinical Infectious Diseases. https://doi.org/10.1093/cid/ciaf079
Vancouver
Adzemovic T, Nalintya E, Fieberg A, Mande E, George K, Yueh S, et al. Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease. Clinical Infectious Diseases. 2025. doi:10.1093/cid/ciaf079
BibTeX
@article{Adzemovic2025,
author = {Adzemovic, Tessa and Nalintya, Elizabeth and Fieberg, Ann and Mande, Emmanuel and George, Katende and Yueh, Spencer and Namakula, Olive and Nerima, Patricia and Dai, Biyue and Meya, David B and Boulware, David R and Rajasingham, Radha},
title = {Diagnostic Accuracy of the Updated FujiLAM II Assay to Detect Tuberculosis in Outpatients With Advanced HIV Disease},
journal = {Clinical Infectious Diseases},
year = {2025},
doi = {10.1093/cid/ciaf079}
}
EUVIMED